|
1
|
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
|
J Clin Oncol
|
2005
|
5.10
|
|
2
|
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
|
Clin Cancer Res
|
2006
|
3.66
|
|
3
|
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia.
|
Nat Genet
|
2012
|
2.26
|
|
4
|
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
|
J Thorac Oncol
|
2006
|
1.75
|
|
5
|
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.
|
Lung Cancer
|
2012
|
1.67
|
|
6
|
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
|
Carcinogenesis
|
2004
|
1.65
|
|
7
|
Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese.
|
Carcinogenesis
|
2008
|
1.57
|
|
8
|
A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population.
|
Nat Genet
|
2012
|
1.51
|
|
9
|
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
|
J Clin Oncol
|
2008
|
1.50
|
|
10
|
Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
|
J Clin Oncol
|
2005
|
1.50
|
|
11
|
Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients.
|
J Thorac Oncol
|
2008
|
1.47
|
|
12
|
Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.
|
J Clin Oncol
|
2004
|
1.42
|
|
13
|
High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients.
|
Cancer Sci
|
2006
|
1.38
|
|
14
|
Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
|
Clin Cancer Res
|
2007
|
1.34
|
|
15
|
Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.
|
Clin Cancer Res
|
2008
|
1.31
|
|
16
|
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
|
Lung Cancer
|
2004
|
1.27
|
|
17
|
Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk.
|
Int J Cancer
|
2005
|
1.22
|
|
18
|
Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes.
|
Carcinogenesis
|
2010
|
1.15
|
|
19
|
Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.
|
Cancer Epidemiol Biomarkers Prev
|
2002
|
1.14
|
|
20
|
Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients.
|
Cancer Sci
|
2003
|
1.08
|
|
21
|
Contribution of the TP53, OGG1, CHRNA3, and HLA-DQA1 genes to the risk for lung squamous cell carcinoma.
|
J Thorac Oncol
|
2011
|
1.07
|
|
22
|
Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
|
Chest
|
2005
|
1.06
|
|
23
|
Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy.
|
Lung Cancer
|
2005
|
1.06
|
|
24
|
Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.
|
Invest New Drugs
|
2011
|
1.02
|
|
25
|
A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
1.02
|
|
26
|
Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial.
|
J Oncol Pract
|
2011
|
1.02
|
|
27
|
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
|
Cancer Chemother Pharmacol
|
2009
|
1.01
|
|
28
|
Association of the OGG1-Ser326Cys polymorphism with lung adenocarcinoma risk.
|
Cancer Sci
|
2006
|
1.00
|
|
29
|
Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
|
J Clin Oncol
|
2010
|
1.00
|
|
30
|
Regulatory nexus of synthesis and degradation deciphers cellular Nrf2 expression levels.
|
Mol Cell Biol
|
2013
|
1.00
|
|
31
|
Identification of a novel polymorphic enhancer of the human CYP3A4 gene.
|
Mol Pharmacol
|
2004
|
0.98
|
|
32
|
Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15.
|
Drug Metab Pharmacokinet
|
2007
|
0.97
|
|
33
|
Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.
|
J Thorac Oncol
|
2011
|
0.96
|
|
34
|
Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
|
Cancer Sci
|
2009
|
0.96
|
|
35
|
Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation.
|
Transplantation
|
2002
|
0.96
|
|
36
|
Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
|
Cancer Sci
|
2004
|
0.95
|
|
37
|
Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
|
J Thorac Oncol
|
2009
|
0.93
|
|
38
|
Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility.
|
Cancer Epidemiol Biomarkers Prev
|
2002
|
0.93
|
|
39
|
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
|
Nat Rev Clin Oncol
|
2009
|
0.93
|
|
40
|
Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
|
Drug Metab Dispos
|
2008
|
0.91
|
|
41
|
Localization of a human lung adenocarcinoma susceptibility locus, possibly syntenic to the mouse Pas1 locus, in the vicinity of the D12S1034 locus on chromosome 12p11.2-p12.1.
|
Carcinogenesis
|
2002
|
0.91
|
|
42
|
Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients.
|
Cancer Sci
|
2006
|
0.90
|
|
43
|
Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk.
|
Biochem Biophys Res Commun
|
2005
|
0.89
|
|
44
|
Association of KRAS polymorphisms with risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias.
|
Carcinogenesis
|
2008
|
0.89
|
|
45
|
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
|
Jpn J Clin Oncol
|
2007
|
0.88
|
|
46
|
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
|
Br J Clin Pharmacol
|
2010
|
0.87
|
|
47
|
Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients.
|
Med Oncol
|
2007
|
0.87
|
|
48
|
Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy.
|
Lung Cancer
|
2008
|
0.87
|
|
49
|
Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinum-based chemotherapy.
|
Am J Clin Oncol
|
2003
|
0.86
|
|
50
|
Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population.
|
Drug Metab Pharmacokinet
|
2006
|
0.85
|
|
51
|
Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients.
|
Radiother Oncol
|
2006
|
0.85
|
|
52
|
Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population.
|
Drug Metab Dispos
|
2005
|
0.84
|
|
53
|
Genetic variations of orosomucoid genes associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer patients.
|
J Pharm Sci
|
2011
|
0.84
|
|
54
|
Small-cell lung cancer with lymphadenopathy in an 18-year-old female nonsmoker.
|
Nat Clin Pract Oncol
|
2006
|
0.84
|
|
55
|
Functional analysis of four naturally occurring variants of human constitutive androstane receptor.
|
Mol Genet Metab
|
2005
|
0.83
|
|
56
|
Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials.
|
Cancer Treat Rev
|
2004
|
0.82
|
|
57
|
Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population.
|
Drug Metab Pharmacokinet
|
2008
|
0.82
|
|
58
|
Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients.
|
Jpn J Clin Oncol
|
2006
|
0.81
|
|
59
|
Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients.
|
Drug Metab Pharmacokinet
|
2009
|
0.81
|
|
60
|
Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses.
|
Radiother Oncol
|
2009
|
0.81
|
|
61
|
Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel.
|
Oncology
|
2008
|
0.80
|
|
62
|
Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer.
|
Lung Cancer
|
2006
|
0.80
|
|
63
|
Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
|
Jpn J Clin Oncol
|
2008
|
0.80
|
|
64
|
A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
|
Cancer Chemother Pharmacol
|
2009
|
0.80
|
|
65
|
Eighteen novel polymorphisms of the CYP2A13 gene in Japanese.
|
Drug Metab Pharmacokinet
|
2003
|
0.80
|
|
66
|
CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population.
|
Pharmacogenet Genomics
|
2007
|
0.80
|
|
67
|
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
|
Cancer Chemother Pharmacol
|
2007
|
0.80
|
|
68
|
Genetic polymorphisms and haplotypes of por, encoding cytochrome p450 oxidoreductase, in a Japanese population.
|
Drug Metab Pharmacokinet
|
2010
|
0.80
|
|
69
|
Association of polymorphisms in the MTH1 gene with small cell lung carcinoma risk.
|
Carcinogenesis
|
2006
|
0.79
|
|
70
|
Genetic variations of VDR/NR1I1 encoding vitamin D receptor in a Japanese population.
|
Drug Metab Pharmacokinet
|
2007
|
0.79
|
|
71
|
A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
0.79
|
|
72
|
Identification of D19S246 as a novel lung adenocarcinoma susceptibility locus by genome survey with 10-cM resolution microsatellite markers.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.79
|
|
73
|
Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
|
Jpn J Clin Oncol
|
2009
|
0.78
|
|
74
|
Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
|
Cancer Chemother Pharmacol
|
2011
|
0.78
|
|
75
|
Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.78
|
|
76
|
A 5'-region polymorphism modulates promoter activity of the tumor suppressor gene MFSD2A.
|
Mol Cancer
|
2011
|
0.78
|
|
77
|
Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or older.
|
Jpn J Clin Oncol
|
2007
|
0.78
|
|
78
|
Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer.
|
Clin Pharmacol Ther
|
2006
|
0.78
|
|
79
|
Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer.
|
Jpn J Clin Oncol
|
2002
|
0.78
|
|
80
|
Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease.
|
J Thorac Oncol
|
2009
|
0.77
|
|
81
|
Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.
|
Jpn J Clin Oncol
|
2003
|
0.77
|
|
82
|
Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
|
Jpn J Clin Oncol
|
2007
|
0.77
|
|
83
|
Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer.
|
Lung Cancer
|
2002
|
0.77
|
|
84
|
Association of CYP19A1 polymorphisms with risks for atypical adenomatous hyperplasia and bronchioloalveolar carcinoma in the lungs.
|
Carcinogenesis
|
2010
|
0.76
|
|
85
|
Genetic variations and haplotype structures of the glutathione S-transferase genes, GSTT1 and GSTM1, in a Japanese patient population.
|
Drug Metab Pharmacokinet
|
2009
|
0.76
|
|
86
|
Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity.
|
Cancer Sci
|
2007
|
0.75
|
|
87
|
Three novel single nucleotide polymorphisms in UGT1A10.
|
Drug Metab Pharmacokinet
|
2002
|
0.75
|
|
88
|
Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy.
|
Oncol Lett
|
2011
|
0.75
|
|
89
|
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.
|
Jpn J Clin Oncol
|
2009
|
0.75
|
|
90
|
Problems with registration-directed clinical trials for lung cancer in Japan.
|
Tohoku J Exp Med
|
2007
|
0.75
|
|
91
|
Differences in the quality of information on the internet about lung cancer between the United States and Japan.
|
J Thorac Oncol
|
2009
|
0.75
|
|
92
|
Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.
|
Jpn J Clin Oncol
|
2007
|
0.75
|
|
93
|
Novel nonsynonymous polymorphisms of the CYP1A1 gene in Japanese.
|
Drug Metab Pharmacokinet
|
2003
|
0.75
|